Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) PT at $35.75

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have received a consensus recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $35.75.

SNN has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Canaccord Genuity Group cut their price objective on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 10th. Finally, Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th.

Smith & Nephew SNATS Stock Down 0.5%

NYSE SNN opened at $32.71 on Thursday. The stock’s 50 day moving average is $32.96 and its 200 day moving average is $34.32. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of Montreal Can grew its position in Smith & Nephew SNATS by 321.6% in the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after purchasing an additional 2,616,301 shares during the period. Yousif Capital Management LLC bought a new stake in shares of Smith & Nephew SNATS in the second quarter worth $217,000. Scharf Investments LLC increased its position in Smith & Nephew SNATS by 0.3% during the second quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock valued at $63,818,000 after acquiring an additional 6,993 shares during the last quarter. Ballentine Partners LLC bought a new position in Smith & Nephew SNATS in the second quarter valued at about $263,000. Finally, Allspring Global Investments Holdings LLC boosted its position in Smith & Nephew SNATS by 4.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock worth $381,000 after purchasing an additional 570 shares during the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.